Innolake Biopharm was Granted Patent Rights for Its In-house Developed Anti-B7H3 ADC with Global Best-in-class Potential
2023-01-30

On January 28, 2023, the first working day of Chinese Rabbit Year, Innolake Biopharm (Hangzhou) Co., Ltd. (hereinafter referred to as "Innolake") received a notice of granting invention patent for its independently developed best-in-class ADC candidate targeting B7H3 (ILB-3101) from China National Intellectual Property Administration. Innolake has built up a systematic global patent strategy for the ILB-3101 program, with the protection scope covering its core antibody, linker-payload, and other related technologies. Following the grant of patent in China, the patent family will also be applied in the major overseas countries, which will provide effective intellectual property protection for the ADC drug candidate for its future market competitiveness and commercial value.


ILB-3101: Newly Designed Anti-B7H3 ADC Molecule

As an emerging drug target against cancer in recent years, B7H3 is specifically overexpressed in a broad range of solid tumors. Developed from Innolake’s two major in-house platforms of antibodies and ADC, ILB-3101 is an antibody-drug conjugate targeting B7H3. Innolake completely own its proprietary rights. Based on its In-house molecular design, screening and optimization of mAbs, linker technology and unique payload selection, ILB-3101 demonstrated the promising pre-clinical data with following key attributes:


1. Compared to the antibodies of two other global leading B7H3 ADC drug candidates, the finally selected B7H3 antibody of ILB-3101 has significant advantages in endocytosis, in-vivo and in-vitro efficacy assay.


2. In terms of linker-payload, Innolake selected a unique toxin, Eribulin as the payload, which has higher potency and better safety profile than camptothecins (e.g., Dxd). Its linker has been specifically designed and proofed to be very stable in plasma. Innolake owns its IP rights.


3. In CDX studies, ILB-3101 has shown superior anti-tumor efficacy in comparison to two other global leading B7H3 ADC drug candidates. Meanwhile, it also demonstrated a wider therapeutic window in pre-toxicity studies of cynomolgus monkeys.


4. Innolake is advancing its pre-clinical studies as scheduled and will submit IND application late of 2023/early of 2024.